A Study to Evaluate the Effectiveness of the Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) in the European Economic Area (EEA) (ACE-536-MDS-005)

15/07/2021
20/02/2024
EU PAS number:
EUPAS42016
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Protocol_2D_Evaluation_aRMMs_for_REBLOZYL

English (471.43 KB - PDF) View document
Study results
Study report
Other information